— Approval follows 20 years of off-label use of compounded formulations of the VEGF inhibitor
July 24, 2026
• 2 min read
The FDA approved the first formulation of bevacizumab specifically for the treatment of neovascular (wet) age-related macular degeneration (nAMD), Outlook Therapeutics announced on Friday.
The approval of bevacizumab-vikg (Lytenava) follows more than 20 years of off-label use of compounded formulations of the VEGF inhibitor for nAMD, a chronic, progressive retinal disease that is one of the leading causes of severe vision loss in older adults. The first clinical application of bevacizumab for nAMD occurred just a year after bevacizumab (Avastin) received initial FDA approval in 2004 as a treatment for metastatic colorectal cancer.
